Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
2 Ro5 violations · MW 1,202.63 Da
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Experimental lipophilicity (logD/logP) and related physicochemical measurements.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 4.4 logD (octanol/water) | Comparable | octanol/water partition (logD) | logD octanol water | Open |
| 2 | 3.7 logD (octanol/water) | Comparable | octanol/water partition (logD) | logD octanol water | Open |
| 3 | 4.06 logD (octanol/water) | Comparable | octanol/water partition (logD) | logD octanol water | Open |
| 4 | 2.92 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 5 | 14 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 6 | 2.9 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 7 | 3.54 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 8 | 2.92 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 9 | 1.4 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
| 10 | -8.96 logP (octanol/water) | Comparable | octanol/water partition (logP, neutral species) | logP octanol water | Open |
Interpretation: Lipophilicity is only comparable within the same partition system (e.g. octanol/water vs 1,9-decadiene/water) and pH; values are never merged across systems.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 44 % | Comparable | Absolute bioavailability in human · human | bioavailability · F· Absolute bioavailability in human · Exact ChEMBL pref name CYCLOSPOR... | Open |
| 2 | 30 % | Comparable | Oral bioavailability in human · human | Route: oral · bioavailability · F· Oral bioavailability in human · Exact ChEMBL pref name CYCLOSPORINE... | Open |
| 3 | 79 % | Comparable | Oral bioavailability in plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during high fat diet phase by HPLC method · human · plasma | Route: oral · bioavailability · F· Oral bioavailability in plasma of healthy human subjects (8 subjects... | Open |
| 4 | 21 % | Comparable | Oral bioavailability in plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase by HPLC method · human · plasma | Route: oral · bioavailability · F· Oral bioavailability in plasma of healthy human subjects (8 subjects... | Open |
| 5 | 29 % | Comparable | Oral bioavailability in Wistar-Han rat at 10 mg/kg after 0.033 to 24 hrs by LC-MS/MS method · rat | Route: oral · bioavailability · F· Oral bioavailability in Wistar-Han rat at 10 mg/kg after 0.033 to 24... | Open |
| 6 | 30 % | Comparable | PepTherDia curated product PK field | Route: TOPICAL, OPHTALMIC, IV, ORAL · 73 · Cyclosporine · exact product name match · exact or normalized match | Open |
| 7 | Observation The effect of milk on the bioavailability of cyclosporine when administered as cyclosporine oral solution, USP MODIFIED has not been evaluated. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: oral · Cyclosporine· bioavailability food effect not evaluated text · The effect of milk on the... | Open |
| 8 | Observation The absolute bioavailability of cyclosporine administered as cyclosporine oral solution, USP MODIFIED has not been determined in adults. In studies of renal transplant, rheumatoid arthritis and psoriasis patients, the mean cyclosporine AUC was approximately 20% to 50% greater and the peak blood cyclosporine concentration (C max ) was approximately 40% to 106% greater following administration of cyclosporine oral solution, USP MODIFIED compared to following administration of Sandimmune (cyclosporine oral solution, USP). | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: oral · Cyclosporine· cyclosporine adult modified bioavailability not determined text · The absol... | Open |
| 9 | Observation In the pediatric population, cyclosporine oral solution, USP MODIFIED also demonstrates an increased bioavailability as compared to Sandimmune (cyclosporine oral solution, USP). In 7 liver de novo transplant patients aged 1.4 to 10 years, the absolute bioavailability of cyclosporine oral solution, USP MODIFIED was 43% (range 30% to 68%) and for Sandimmune (cyclosporine oral solution, USP) in the same individuals absolute bioavailability was 28% (range 17% to 42%). | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: oral · Cyclosporine· cyclosporine pediatric formulation bioavailability text · In the pediatric... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 476000 ng*h/mL | Comparable | AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method · rat | Route: iv · area under curve · AUC· AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, iv after 0.033... | Open |
| 2 | 13800 ng*h/mL | Comparable | AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method · rat | area under curve · AUC· AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, po after 0.033... | Open |
| 3 | 11556 ng*h/mL | Comparable | AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during high fat diet phase by HPLC method · human · plasma | area under curve · AUC· AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg,... | Open |
| 4 | 4471 ng*h/mL | Comparable | AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during low fat diet phase by HPLC method · human · plasma | area under curve · AUC· AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg,... | Open |
| 5 | 5971 ng*h/mL | Comparable | AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during high fat diet phase by HPLC method · human · plasma | Route: iv · area under curve · AUC· AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg,... | Open |
| 6 | 8799 ng*h/mL | Comparable | AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during low fat diet phase by HPLC method · human · plasma | Route: iv · area under curve · AUC· AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg,... | Open |
| 7 | 7187 ng*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table auc mean de novo liver transplant 5 week 4 n 18 ·... | Open |
| 8 | 2324 ng*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table auc mean de novo psoriasis 6 week 4 n 18 · Pharmac... | Open |
| 9 | 8772 ng*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table auc mean de novo renal transplant 4 week 4 n 37 ·... | Open |
| 10 | 2641 ng*h/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table auc mean de novo rheumatoid arthritis 6 n 23 · Pha... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1712.91 nM | Comparable | Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 1.8 +/- 0.3 hrs during high fat diet phase by HPLC method · human · plasma | max concentration · Cmax· Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/... | Open |
| 2 | 618.64 nM | Comparable | Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 2.8 +/- 0.7 hrs during low fat diet phase by HPLC method · human · plasma | max concentration · Cmax· Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/... | Open |
| 3 | 1047.7 nM | Comparable | Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 6.8 +/- 1.1 hrs during high fat diet phase by HPLC method · human · plasma | max concentration · Cmax· Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/... | Open |
| 4 | 303.5 nM | Comparable | Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 8.4 +/- 0.9 hrs during low fat diet phase by HPLC method · human · plasma | max concentration · Cmax· Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/... | Open |
| 5 | 1197.38 nM | Comparable | Cmax in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method · rat | max concentration · Cmax· Cmax in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by... | Open |
| 6 | 1555 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table cmax mean de novo liver transplant 5 week 4 n 18 ·... | Open |
| 7 | 655 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table cmax mean de novo psoriasis 6 week 4 n 18 · Pharma... | Open |
| 8 | 1802 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table cmax mean de novo renal transplant 4 week 4 n 37 ·... | Open |
| 9 | 728 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table cmax mean de novo rheumatoid arthritis 6 n 23 · Ph... | Open |
| 10 | 1333 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table cmax mean stable renal transplant 4 n 55 · Pharmac... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1.5-2 hours 5400-7200 seconds | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: oral · Cyclosporine· cyclosporine adult tmax range · Following oral administration of cyclospori... | Open |
| 2 | 1.8 hr 6480 seconds | Comparable | Tmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during high fat diet phase by HPLC method · human · plasma | time to max concentration · Tmax· Tmax in plasma of healthy human subjects (8 subjects) a... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 3-5 L/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Cyclosporine· volume of distribution iv reported range · The steady state volume of distr... | Open |
| 2 | 3.3 L/kg | Comparable | Volume of distribution at steady state in human · human | volume of distribution · Vdss· Volume of distribution at steady state in human · Exact Ch... | Open |
| 3 | 3.3 L/kg | Comparable | Volume of distribution at steady state in human after iv administration · human | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... | Open |
| 4 | 1.85 L/kg | Comparable | Volume of distribution at steady state in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method · human · plasma | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in plasma of health... | Open |
| 5 | 1.19 L/kg | Comparable | Volume of distribution at steady state in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method · human · plasma | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in plasma of health... | Open |
| 6 | 1.2 L/kg | Comparable | Volume of distribution at steady state in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method · rat | Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in Wistar-Han rat a... | Open |
| 7 | 0.806 L/kg | Comparable | Volume of distribution in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method · human · plasma | Route: iv · volume of distribution · Vd· Volume of distribution in plasma of healthy human subjects (... | Open |
| 8 | 0.609 L/kg | Comparable | Volume of distribution in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method · human · plasma | Route: iv · volume of distribution · Vd· Volume of distribution in plasma of healthy human subjects (... | Open |
| 9 | Observation In a study performed in 4 subjects with end-stage renal disease (creatinine clearance < 5 mL/min), an intravenous infusion of 3.5 mg/kg of cyclosporine over 4 hours administered at the end of a hemodialysis session resulted in a mean volume of distribution (Vdss) of 3.49 L/kg and systemic clearance (CL) of 0.369 L/hr/kg. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: intravenous · Cyclosporine· cyclosporine esrd hemodialysis vd clearance context text · In a study perfo... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | ~ 90 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Cyclosporine· plasma binding in plasma bound to proteins percent · In plasma, approximate... | Open |
| 2 | > 99 % | Reported | Percentage bound in human plasma at 1 uM after 5 hrs by dialysis chamber method · human · plasma | plasma protein binding · PPB· Percentage bound in human plasma at 1 uM after 5 hrs by dia... | Open |
| 3 | > 99.6 % | Reported | Plasma protein binding in human after 30 min by ultrafiltration · human · plasma | plasma protein binding · PPB· Plasma protein binding in human after 30 min by ultrafiltra... | Open |
| 4 | Observation About 50% of the administered dose is taken up by erythrocytes while about 34% is bound to lipoproteins. Prescribing information for Sandimmune states that 90% is mainly bound to lipoproteins. | Reported | PepTherDia curated product PK field · plasma protein | Route: TOPICAL, OPHTALMIC, IV, ORAL · 73 · Cyclosporine · exact product name match · exact or normalized match | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 11.62 mL/min/kg | Comparable | Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method · human · plasma | Route: iv · clearance · CL· Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv... | Open |
| 2 | 7.85 mL/min/kg | Comparable | Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method · human · plasma | Route: iv · clearance · CL· Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv... | Open |
| 3 | 3.5 mL/min/kg | Comparable | Clearance in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method · rat | Route: iv · clearance · CL· Clearance in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-M... | Open |
| 4 | 8.6 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min kg mean de novo liver transplant 5 week... | Open |
| 5 | 10.2 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min kg mean de novo psoriasis 6 week 4 n 18... | Open |
| 6 | 7.8 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min kg mean de novo renal transplant 4 week... | Open |
| 7 | 8.3 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min kg mean de novo rheumatoid arthritis 6... | Open |
| 8 | 5.9 mL/min/kg | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min kg mean stable renal transplant 4 n 55... | Open |
| 9 | 577 mL/min | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min mean de novo liver transplant 5 week 4... | Open |
| 10 | 723 mL/min | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Cyclosporine· cyclosporine adult table clf ml min mean de novo psoriasis 6 week 4 n 18 ·... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +3 more | No reported alias | 0 identity 56 evidence |
PubMed 2391396 | DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +2 more | No reported alias | 0 identity 17 evidence |
PubMed 25950816 | DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +1 more | No reported alias | 0 identity 6 evidence |
Reference link | DistributionExposure Bioavailability, Plasma Protein Binding | No reported alias | 1 identity 2 evidence |
PubMed 20070106 | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 0 identity 2 evidence |
DOI 10.1039/C1MD00227A | DistributionPhyschem Lipophilicity, Plasma Protein Binding | No reported alias | 0 identity 2 evidence |
DOI 10.1021/jm00076a002 | Physchem Lipophilicity | No reported alias | 0 identity 2 evidence |
DOI 10.1021/acs.jmedchem.1c00580 | Physchem Lipophilicity | No reported alias | 0 identity 2 evidence |
PubMed 19445515 | Persistence Clearance | No reported alias | 0 identity 1 evidence |
PubMed 20373811 | Exposure Bioavailability | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0020556' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.